Dehkharghani S, Kang J, Saindane A M
From Neuroradiology Division, Department of Radiology and Imaging Sciences (S.D., A.M.S.), Emory University Hospital, Atlanta, Georgia.
AJNR Am J Neuroradiol. 2014 Mar;35(3):450-6. doi: 10.3174/ajnr.A3693. Epub 2013 Aug 22.
Time-resolved MRA with the use of bolus injection of paramagnetic agents has proved valuable in neurovascular imaging. Standard contrast agents have limited blood-pool residence times, motivating the development of highly protein-bound blood-pool agents with greater relaxivity and longer intravascular residence, affording improved image quality at lesser doses. This study represents the first comparison of blood-pool agents to standard agents in time-resolved cerebral MRA.
One hundred datasets were acquired at 1.5 T by use of a standardized, time-resolved MRA protocol. Patients received either unit dosing of a standard extracellular agent at 0.1 mmol/kg or a blood-pool agent at 0.03 mmol/kg. Peak arterial and venous enhancement phases were identified and subsequently scored qualitatively by use of a 4-point Likert scale, with attention to 6 vascular segments: 1) intracranial ICA; 2) MCA M1; 3) MCA M2; 4) MCA M3; 5) deep cerebral veins; and 6) dural venous sinuses.
Fifty MR angiographies were acquired with each agent. No significant differences were found between agents in generation of uncontaminated arteriograms. Blood-pool agents, at 67% dose reduction, were of significantly greater quality across most vascular segments, including ICA (P = .019), M2 (P = .003), and M3 (P < .01). Superiority in the M1 segment approached significance (P = .059). Significantly better venographic quality was noted for deep venous structures (P = .016) with the use of blood-pool agents.
Blood-pool agents provide superior demonstration of most intracranial vessels in time-resolved MRA compared with standard agents, at reduced doses. The greater relaxation enhancement and more favorable dosing profile make blood-pool agents superior to standard agents for use in cerebral time-resolved MRA.
使用顺磁性造影剂团注的时间分辨磁共振血管造影(MRA)已被证明在神经血管成像中具有重要价值。标准造影剂在血池中的停留时间有限,这促使人们研发具有更高弛豫率和更长血管内停留时间的高蛋白结合血池造影剂,以便在较低剂量下提供更好的图像质量。本研究是首次在时间分辨脑MRA中对血池造影剂和标准造影剂进行比较。
使用标准化的时间分辨MRA方案在1.5T下采集了100个数据集。患者接受0.1mmol/kg的标准细胞外造影剂单次给药或0.03mmol/kg的血池造影剂。确定动脉和静脉强化峰值期,随后使用4级李克特量表进行定性评分,关注6个血管节段:1)颅内颈内动脉(ICA);2)大脑中动脉M1段;3)大脑中动脉M2段;4)大脑中动脉M3段;5)大脑深静脉;6)硬脑膜静脉窦。
每种造影剂均采集了50例磁共振血管造影。在生成未受污染的动脉造影方面,两种造影剂之间未发现显著差异。血池造影剂剂量降低67%,在大多数血管节段,包括ICA(P = 0.019)、M2段(P = 0.003)和M3段(P < 0.01),质量明显更高。M1段的优势接近显著水平(P = 0.059)。使用血池造影剂时,大脑深静脉结构的静脉造影质量明显更好(P = 0.016)。
与标准造影剂相比,血池造影剂在时间分辨MRA中以更低剂量就能更好地显示大多数颅内血管。更大的弛豫增强和更有利的给药方案使血池造影剂在脑时间分辨MRA中优于标准造影剂。